Click on image to view larger version.

Figure 4 Odds ratios for in-hospital adverse outcomes in patients with and without thrombus enrolled in glycoprotein IIb/IIIa inhibitor trials (Evaluation of 7E3 for the Prevention of Ischemic Complications [EPIC] and Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II [IMPACT-II]). These models were adjusted for the specific trials patients were enrolled in, age, history of angina, history of diabetes mellitus, prior coronary intervention, prior coronary artery bypass grafting, thrombus, treatment (IIb/IIIa inhibitors) and treatment-thrombus interaction. Patients without thrombus showed a clear benefit from treatment, unlike patients with thrombus. MI = myocardial infarction.